Ovid Therapeutics (OVID) Stock Statistics & Valuation Metrics

Ovid Therapeutics has a market cap or net worth of $20.40M. The enterprise value is $27.98M.

Ovid Therapeutics has 71.08M shares outstanding. The number of shares has decreased by -2.65% in one year.

Ovid Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -74.58%.

The current PE Ratio of Ovid Therapeutics is -2.50. Ovid Therapeutics’s PEG ratio is 0.05.

In the last 12 months, Ovid Therapeutics had revenue of $566.00K and earned -$26.43M in profits. Earnings per share was -$0.38.

In the last 12 months, operating cash flow was -$55.96M and capital expenditures -$71.00K, giving a free cash flow of -$56.00M billion.

Ovid Therapeutics pays an annual dividend of , resulting in a dividend yield of

Ovid Therapeutics upcoming earnings date is May 8, 2025, TBA.

Ovid Therapeutics as a current ratio of 5.32, with Debt / Equity ratio of 0.02

In the past 12 months, Ovid Therapeutics has paid $92.72K in taxes.

Ovid Therapeutics EV to EBITDA ratio is -0.67, with an EV/FCF ratio of -0.74.

Ovid Therapeutics has $53.08M in cash and marketable securities with $14.76M in debt, giving a net cash position of -$38.32M billion.

Gross margin is 100.00%, with operating margin of -10933.75%, and net profit margin of -4670.14%.

The average price target for Ovid Therapeutics is $3.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy